PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
7 hedge funds and large institutions have $12K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
29% less capital invested
Capital invested by funds: $17K → $12K (-$5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIA
LBMC Investment Advisors
Brentwood,
Tennessee
|
+$1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HFBOT
1
Home Federal Bank of Tennessee
Knoxville,
Tennessee
| $5K | – | – | – |
|
|
DT
2
Diversified Trust
Memphis,
Tennessee
| $2K | – | – | – |
|
|
LDB
3
Lee, Danner & Bass
Nashville,
Tennessee
| $2K | – | – | – |
|
|
ACM
4
Academy Capital Management
Waco,
Texas
| $1K | – | – | – |
|
|
AA
5
Ancora Advisors
Cleveland,
Ohio
| $1K | – | – | – |
|
|
LIA
6
LBMC Investment Advisors
Brentwood,
Tennessee
| $1K | +$1K | +22,000 | New |
|
|
7
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$3K | -57,659 | Closed |
|
PVCT Hedge Fund Activity: Q3 2022 in Review
7 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q3 2022, worth a combined $12K — down 29% from $17K a quarter earlier.
Fund positioning in PVCT was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was LBMC Investment Advisors, opening a new position worth an estimated $1K. The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $3K sold.
- 7 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $12K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q3 2022, down 29% quarter-over-quarter.
- 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q3 2022 and 1 closed out, a net change of 0 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q3 2022 was LBMC Investment Advisors, an estimated $1K added.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q3 2022 was CAPTRUST Financial Advisors, an estimated $3K sold.
Based on aggregated 13F filings for Q3 2022.